# A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

> **NCT06319456** · PHASE3 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 344 (estimated)

## Conditions studied

- CLL/SLL

## Interventions

- **DRUG:** Lisaftoclax (APG-2575)
- **DRUG:** Acalabrutinib
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide，CTX
- **DRUG:** Rituximab
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT06319456
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-07
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06319456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06319456, "A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06319456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*